Abstract: A compound 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranoxyl)-5-methyl-2(1H)-pyr imidinone and its use in a method of generating (forming, providing) 3'-azido-3'-deoxythymidine (zidovudine sometimes referred to as AZT) in the body of an animal (a mammal such as human) by systemically administering 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranosyl)-5-methyl-2(1H)-pyr iminone to said animal (mammal such as a human) is disclosed. AZT is approved and used for treating HIV infections, e.g., AIDS and ARC in humans and also has activity against gram-negative bacteria in animals.
Type:
Grant
Filed:
September 16, 1988
Date of Patent:
August 20, 1991
Assignee:
Burroughs Wellcome Co.
Inventors:
Sammy R. Shaver, George A. Freeman, Janet L. Rideout
Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
Abstract: The invention is a method for using 1-(.beta.-D-arabinofuranosyl)-5-propynyluracil or its salts as the active ingredient in pharmaceutical compositions in the treatment of varicella zoster viral infections whether expressed as chicken pox or shingles.
Abstract: The present invention is concerned with methods for the treatment and diagnosis of pulmonary hypertension which comprise the administration of an effective amount of a compound of formula (I) ##STR1## wherein X is hydrogen or methyl;Y is --O-- or --CH.sub.2 --;R is --C(R.sup.1)(R.sup.2)CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 wherein R.sup.1 and R.sup.2, which may be the same or different, are selected from hydrogen and halogen; andthe dotted line represents an optional double bond; andpharmaceutically acceptable salts and acid derivatives thereof.Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.
Type:
Grant
Filed:
October 13, 1989
Date of Patent:
July 2, 1991
Assignee:
Burroughs Wellcome Co.
Inventors:
Anjaneyulu S. Tadepalli, Brendan J. R. Whittle
Abstract: The present invention relates to a novel ribonucleotide reductase inhibitor and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especially viruses of the herpes group.
Abstract: The present invention provides a compound selected from:N-[4-(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-2-flurobenzoyl] -(L)-glutamic acid,N-[4-( 3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-flurobenzoyl ]-(L)-glutamic acid,N-[4 -(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-methylbenzoyl ]-(L)-glutamic acid,N-[4-( 2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-(methoxy)benzoy l](L)-glutamic acid andN-[4-(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-2-chlorobenzoyl ](L)-glutamic acid,or a salt thereof, methods for the preparation of the compounds, intermediates in their preparations, pharmaceutical formulations containing them, and their use in the treatment of tumors.
Abstract: The present invention is concerned with the compound of formula (I) ##STR1## and esters and acid addition salts thereof having positive inotrope effect.
Type:
Grant
Filed:
August 24, 1989
Date of Patent:
April 23, 1991
Assignee:
Burroughs Wellcome Co.
Inventors:
Richard M. Welch, Alan R. Brown, Arthur P. Phillips
Abstract: The present invention provides a compound of formula (I): ##STR1## wherein Y is oxygen; R.sup.2 and R.sup.3 are the same or different and are hydrogen or C.sub.1-4 alkyl; R.sup.4 is NR.sup.11 R.sup.12 ; R.sup.11, R.sup.12, R.sup.5 and R.sup.6 are the same or different and are hydrogen, C.sub.1-4 alkyl or C.sub.1-12 acyl; R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are the same or different and are hydrogen, halo, C.sub.1-4 haloalkyl, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; and n is 2, 3, 4 or 5; m is 0 or an integer from 1 to 5; or a salt thereof, methods for the preparation of the compounds of the formula (I), intermediates in their preparations, pharmaceutical formulations containing them, and their use in the treatment of neoplastic growth.
Abstract: The present invention relates to certain amino acid exters of the purine nucleoside acyclovir, pharmaceutically acceptable salts thereof and their use in the treatment of herpes virus infections. The invention also includes pharmaceutical formulations and processes for the preparation of such compounds.
Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Type:
Grant
Filed:
February 8, 1988
Date of Patent:
October 17, 1989
Assignee:
Burroughs Wellcome Co.
Inventors:
Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Type:
Grant
Filed:
October 20, 1987
Date of Patent:
June 6, 1989
Assignee:
Burroughs Wellcome Co.
Inventors:
Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Type:
Grant
Filed:
October 20, 1987
Date of Patent:
May 23, 1989
Assignee:
Burroughs Wellcome Co.
Inventors:
Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Type:
Grant
Filed:
October 21, 1987
Date of Patent:
May 9, 1989
Assignee:
Burroughs Wellcome Co.
Inventors:
Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5.dbd.-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Type:
Grant
Filed:
October 21, 1987
Date of Patent:
April 4, 1989
Assignee:
Burroughs Wellcome Co.
Inventors:
Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Type:
Grant
Filed:
September 17, 1985
Date of Patent:
February 9, 1988
Assignee:
Burroughs Wellcome Co.
Inventors:
Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
Abstract: A chair, suitable for aircraft or other transport, which is convertible into a berth, comprising in combination(a) a seat base,(b) a back rest, movably mounted on the rear portion of the base so as to be capable of being reclined from the erect, sitting position into a substantially horizontal, stretched berth position,(c) a leg rest, mounted at the front portion of the base, and capable of being moved from an unobstructive position under the base into a substantially horizontal berth position, and(d) a supporting means for retaining and locating the base berth in a sitting position and alternatively in a predetermined berth position;wherein the supporting means is adapted and located so as to permit in use a second, chair to be stretched and moved into a berth position underneath said first chair, whenever the latter is in the elevated berth position with the rests in the stretched state; and in particular to such pair of chairs and rows thereof providing compartmental arrangements.